Corporate News     14-Mar-22
Alembic Pharmaceuticals receives USFDA approval for Macitentan Tablets
Alembic Pharmaceuticals today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Macitentan Tablets, 10 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Opsumit Tablets, 10 mg, of Actelion Pharmaceuticals US, Inc. (Actelion). Macitentan Tablets are an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Macitentan Tablets also reduced hospitalization for PAH. It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses."

Macitentan Tablets, 10 mg have an estimated market size of US$ 797 million for twelve months ending Dec 2021 according to IQVIA.

Alembic has received year to date (YTD) 22 approvals (15 final approvals and 7 tentative approvals) and a cumulative total of 161 ANDA approvals (138 final approvals and 23 tentative approvals) from USFDA.

Previous News
  Alembic Pharma rises after receiving USFDA nod for cancer drug
 ( Hot Pursuit - 04-Jul-24   13:00 )
  Alembic Pharmaceuticals receives USFDA approval for Dabigatran Etexilate Capsules
 ( Corporate News - 18-Jun-24   18:52 )
  Alembic Pharma gets US FDA nod for heart failure-treatment drug
 ( Hot Pursuit - 30-May-24   14:05 )
  Alembic Pharma Q3 PAT slips 29% YoY; R&D spend at Rs 157 crore
 ( Hot Pursuit - 02-Feb-23   10:41 )
  Volumes spurt at Alembic Pharmaceuticals Ltd counter
 ( Hot Pursuit - 20-Jul-23   14:30 )
  Alembic Pharmaceuticals receives USFDA approval for Sacubitril and Valsartan Tablets
 ( Corporate News - 30-May-24   14:49 )
  USFDA inspects Alembic Pharma's solid oral formulation facility at Jarod
 ( Corporate News - 19-Dec-22   12:51 )
  Intellect Design Arena Ltd leads losers in 'A' group
 ( Hot Pursuit - 10-May-24   15:00 )
  Alembic Pharma gets USFDA nod for stroke and blood clots drug
 ( Hot Pursuit - 18-Jun-24   14:27 )
  CRISIL reaffirms ratings of Alembic Pharmaceuticals with 'stable' outlook
 ( Hot Pursuit - 08-Mar-24   11:22 )
  Alembic receives USFDA approval for Diclofenac Sodium Topical Solution
 ( Corporate News - 01-Dec-22   11:17 )
Other Stories
  Board of Delhivery approves alteration in capital clause of MoA
  05-Jul-24   19:32
  J B Chemicals & Pharmaceuticals appoints director
  05-Jul-24   19:30
  Infosys announces resignation of senior management personnel
  05-Jul-24   19:22
  JLR Q1 FY25 retail sales up 9% on YoY basis
  05-Jul-24   19:08
  Bajaj Auto launches world's first CNG motorcycle 'Freedom'
  05-Jul-24   18:59
  Agenda for board meeting of Power Grid Corporation of India
  05-Jul-24   18:46
  Board of Bank of Baroda approves raising additional capital up to Rs 7,500 cr in FY25
  05-Jul-24   18:06
  Vipul to hold board meeting
  05-Jul-24   17:15
  Markobenz Ventures to convene board meeting
  05-Jul-24   17:15
  Dhanashree Electronics to declare Quarterly Result
  05-Jul-24   17:15
Back Top